International Journal of Pharmacology1811-77751812-5700Asian Network for Scientific Information10.3923/ijp.2019.933.943ChenYen-Jen YuanKuo-Ching JayakumarThanasekaran HsiaChih-Hsuan HsiaChih-Wei VelusamyMarappan ChouDuen-Suey HouShaw-Min 82019158Background and Objective: Platinum compounds are largely replaced by iridium (Ir)-based metal complexes as these compounds display encouraging anticancer effects with less side effects. Iridium compounds exhibited notable properties against platelet activation, however, its effect anti-neuroinflammatory effect remain unknown. Therefore, a comparative anti-neuroinflammatory effect of novel iridium compounds (Ir-3, Ir-6 and Ir-11) were investigated in LPS-induced BV2 microglial cells. Materials and Methods: Quantitative real-time PCR was performed to detect the mRNA expression of COX-2, iNOS, TNF-α, IL-1β, IL-6 and anti-inflammatory cytokines Arg-1 and IL-10. Protein expression of iNOS and IL-1β was tested by Western blotting assay. The oxygen-glucose deprivation-reperfusion (OGD/R)-induced inflammation was also evaluated in BV2 cells. Results: The results showed that LPS-treated BV2 microglia had fewer branches that appeared to be resorbed into the cell body, whereas control microglia showed small soma with distal arborization. The LPS induced COX-2, iNOS, TNF-α, IL-1β and IL-6 and decreased Arg-1 and IL-10 mRNA expressions. Among the tested iridium compounds, Ir-6 attenuated the mRNA and protein expression of iNOS and T NF-α and protein expression of IL-1β. The OGD/R significantly increased COX-2, iNOS, TNF-α and IL-1β mRNA in BV2 microglia cells. Conclusion: These results suggest that Ir-6 can be consider as a novel anti-neuroinflammatory agent to treat neurodegenerative diseases via regulating cytokines and iNOS.]]>Kempuraj, D., R. Thangavel, P.A. Natteru, G.P. Selvakumar and D. Saeed et al.,20162016Glass, C.K., K. Saijo, B. Winner, M.C. Marchetto and F.H. Gage,2010140918934Magni, P., M. Ruscica, E. Dozio, E. Rizzi, G. Beretta and R.M. Facino,20122614051409Kwon, Y.W., S.Y. Cheon, S.Y. Park, J. Song and J.H. Lee,20172017Varnum, M.M. and T. Ikezu,201260251266Dong, Y., L. Liu, X. Shan, J. Tang and B. Xia et al.,2017108272276Kovala-Demertzi, D.,200079153157Konstandinidou, M., A. Kourounakis, M. Yiangou, L. Hadjipetrou, D. Kovala-Demertzi, S. Hadjikakou and M. Demertzis,1998706369Chohan, Z.H., M.S. Iqbal, H.S. Iqbal, A. Scozzafava and C.T. Supuran,2002178791Kale, M.A., R. Shelke and R.B. Nawale,2014133644Leung, C.H., S. Lin, H.J. Zhong and D.L. Ma,20146871884Gasser, G., I. Ott and N. Metzler-Nolte,201154325Hsia, C.W., M. Velusamy, J.T. Tsao, C.H. Hsia and D.S. Chou et al.,20172017Shyu, K.G., M. Velusamy, C.W. Hsia, C.H. Yang and C.H. Hsia et al.,20184125892600Shyu, R.S., T. Khamrang, J.R. Sheu, C.W. Hsia and M. Velusamy et al.,20182018Sheu, J.R., Z.C. Chen, M.J. Hsu, S.H. Wang and K.W. Jung et al.,2018229991013Zhou, J.M., S.S. Gu, W.H. Mei, J. Zhou, Z.Z. Wang and W. Xiao,20162110371053Barnham, K.J., C.L. Masters and A.I. Bush,20043205214Perry, V.H. and C. Holmes,201410217224Drechsel, D.A., A.G. Estevez, L. Barbeito and J.S. Beckman,201222251264Tomaz, V.S., R.C. Cordeiro, A.M.N. Costa, D.F. de Lucena and H.V. Nobre Jr. et al.,2014268236246Czapski, G.A., B. Gajkowska and J.B. Strosznajder,201013568594Kim, B.W., S.V. More, Y.S. Yun, H.M. Ko and J.H. Kwak et al.,2016in vitro via inhibiting NF-kB and p38 MAPK pathways.]]>37334343Wen, X., L. Xiao, Z. Zhong, L. Wang, Z. Li, X. Pan and Z. Liu,201786937069385Manso, M.A., C. Escudero, M. Alijo and R. Lopez-Fandino,20026519921996